Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $31.00 by Analysts at Wedbush

Viridian Therapeutics (NASDAQ:VRDN) had its price target cut by Wedbush from $37.00 to $31.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also recently issued research reports about the company. Wells Fargo & Company reduced their price target on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. Needham & Company LLC dropped their price objective on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. The Goldman Sachs Group dropped their price objective on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Royal Bank Of Canada dropped their price objective on Viridian Therapeutics from $42.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.57.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $14.47 on Wednesday. Viridian Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $34.29. The business has a 50-day moving average of $27.19 and a two-hundred day moving average of $27.73. The stock has a market capitalization of $1.48 billion, a P/E ratio of -4.40 and a beta of 1.16. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. On average, equities research analysts predict that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC bought a new position in shares of Viridian Therapeutics in the fourth quarter worth about $46,680,000. Seven Fleet Capital Management LP bought a new position in Viridian Therapeutics during the fourth quarter valued at about $456,000. Virtu Financial LLC bought a new position in Viridian Therapeutics during the fourth quarter valued at about $531,000. Invesco Ltd. increased its stake in Viridian Therapeutics by 127.1% during the fourth quarter. Invesco Ltd. now owns 183,468 shares of the company’s stock valued at $5,710,000 after acquiring an additional 102,676 shares during the period. Finally, XTX Topco Ltd bought a new position in Viridian Therapeutics during the fourth quarter valued at about $1,464,000.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Multiple brokerages lowered price targets but maintained bullish ratings, leaving large implied upside (Goldman Sachs cut to $31 but stayed “buy”; Wedbush cut to $31 with “outperform”; RBC cut to $30 with “outperform”) — this keeps analyst support visible and may attract value-seeking buyers. Benzinga
• Neutral Sentiment: Market write-ups are revisiting VRDN’s valuation after a multi-month pullback, offering analysis for investors on how current price compares to fundamentals and runway — useful but not catalytic by itself. A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi‑Month Share Price Pullback
• Neutral Sentiment: Unusually large options volume was reported, indicating elevated speculative or hedging flows that can amplify intraday moves but do not by themselves change fundamentals. Viridian Therapeutics Sees Unusually Large Options Volume (NASDAQ:VRDN)
• Neutral Sentiment: Analyst commentary roundups (e.g., The Globe and Mail) are providing context on VRDN and peers, which helps investors interpret competitive dynamics but contains no single new catalyst. Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
• Negative Sentiment: Critical analysis argues VRDN’s elegrobart Phase 3 readouts don’t pose a meaningful challenge to Amgen’s position, highlighting competitive risk that can pressure long-term revenue expectations for VRDN’s programs. Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen
• Negative Sentiment: Coverage noting VRDN shares hit 9‑month lows and tying the move to Amgen-related competitive concerns reinforces downside narratives and could keep selling pressure if pipeline comparisons remain unfavorable. VRDN stock falls to 9-month lows – what’s the Amgen connection?

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.